Диссертация (1335876), страница 55
Текст из файла (страница 55)
– Vol. 10,№ 9. – P. 1479-1484.219.Improved therapeutic index of carboplatin plus cyclophosphamide versuscisplatin plus cyclophosphamide: final report by the Southwest Oncology Groupof a phase III randomized trial in stages III and IV ovarian cancer [Text] /D.S. Alberts, S. Green, E.V. Hannigan [et al.] // J.
Clin. Oncol. – 1992. – Vol. 10,№ 5. – P. 706-717.220.Incorporation of bevacizumab in the primary treatment of ovarian cancer[Text] / R.A. Burger, M.F. Brady, M.A. Bookman [et al.] // N. Engl. J. Med. –2011. – Vol. 365, № 26. – P. 2473-2483.221.Insulin-dependent leptin expression in breast cancer cells [Text] /V. Bartella, S. Cascio, E. Fiorio [et al.] // Cancer Res.
– 2008. – Vol. 68, № 12. –P. 4919-4927.222.International Collaborative Ovarian Neoplasm trial 1 and AdjuvantChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trialsof adjuvant chemotherapy in patients with early-stage ovarian carcinoma [Text] /J.B. Trimbos, M. Parmar, I. Vergote [et al.] // J. Natl. Cancer Inst. – 2003. –Vol.
95, № 2. – P. 105-112.223.International Collaborative Ovarian Neoplasm trial 1: a randomized trial ofadjuvant chemotherapy in women with early-stage ovarian cancer [Text] /N. Colombo, D. Guthrie, S. Chiari [et al.] // J. Natl. Cancer Inst. – 2003.
– Vol. 95,№ 2. – P. 125-132.320224.International trends in incidence of cervical cancer: II. Squamous-cellcarcinoma [Text] / A.P. Vizcaino, V. Moreno, F.X. Bosch [et al.] // Int. J. Cancer. –2000. – Vol. 86, № 3. – P. 429-435.225.Intraperitoneal chemotherapy in the first-line treatment of women with stageIII epithelial ovarian cancer: a systematic review with metaanalyses [Text] / L. Elit,T.K. Oliver, A. Covens [et al.] // Cancer. – 2007. – Vol. 109, № 4.
– P. 692-702.226.Intraperitoneal cisplatin and paclitaxel in ovarian cancer [Text] /D.K. Armstrong, B. Bundy, L. Wenzel [et al.] // N. Engl. J. Med. – 2006. – Vol.354, № 1. – P. 34-43.227.Intraperitoneal cisplatin plus intravenous cyclophosphamide versusintravenous cisplatin plus intravenous cyclophosphamide for stage III ovariancancer [Text] / D.S. Alberts, P.Y.
Liu, E.V. Hannigan [et al.] // N. Engl. J. Med. –1996. – Vol. 335, № 26. – P. 1950-1955.228.Jaaback, K. Intraperitoneal chemotherapy for the initial management ofprimary epithelial ovarian cancer [Electronic resource] / K. Jaaback, N. Johnson //Cochrane Database Syst. Rev. – 2006. – № 1. – CD005340.229.Jin, X.W. New cervical cancer screening strategy: combined Pap and HPVtesting [Text] / X.W. Jin, K.
Zanotti, B. Yen-Liberman // Cleve. Clin. J. Med. –2005. – Vol. 72, № 2. – P. 141-148.230.Kristensen, G.B. Epithelial ovarian carcinoma [Text] / G.B. Kristensen,C. Trope // Lancet. – 1997. – Vol. 349, № 9045. – P. 113-117.231.Lanciano, R.M. A reappraisal of the International Federation of Gynecologyand Obstetrics staging system for cervical cancer. A study of patterns of care [Text] /R.M. Lanciano, M. Won, G.E. Hanks // Cancer. – 1992. – Vol. 69, № 2.
– P. 482487.232.Liu, Y. Links between alcohol consumption and breast cancer: a look at theevidence [Text] / Y. Liu, N. Nguyen, G.A. Colditz // Womens Health (Lond). –2015. – Vol. 11, № 1. – P. 65-77.233.Long-term results of dose-dense paclitaxel and carboplatin versusconventional paclitaxel and carboplatin for treatment of advanced epithelial321ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised,controlled, open-label trial [Text] / N. Katsumata, M.
Yasuda, S. Isonishi [et al.] //Lancet Oncol. – 2013. – Vol. 14, № 10. – P. 1020-1026.234.Long-term survival of advanced refractory ovarian carcinoma patients withsmall-volume disease treated with intraperitoneal chemotherapy [Text] /S.B. Howell, S. Zimm, M.
Markman [et al.] // J. Clin. Oncol. – 1987. – Vol. 5,№ 10. – P. 1607-1612.235.Mathew, A. Trends in incidence and mortality rates of squamous cellcarcinoma and adenocarcinoma of cervix-worldwide [Text] / A. Mathew,P.S. George // Asian. Pac. J. Cancer Prev. – 2009. – Vol. 10, № 4.
– P. 645-650.236.Meta-analysis of studies of alcohol and breast cancer with consideration ofthe methodological issues [Text] / J. Key, S. Hodgson, R.Z. Omar [et al.] // CancerCauses Control. – 2006. – Vol. 17, № 6. – P. 759-770.237.Metabolic factors and the risk of pancreatic cancer: a prospective analysis ofalmost 580,000 men and women in the Metabolic Syndrome and Cancer Project[Text] / D. Johansen, T.
Stocks, H. Jonsson [et al.] // Cancer Epidemiol. BiomarkersPrev. – 2010. – Vol. 19, № 9. – P. 2307-2317.238.Metabolic syndrome and breast cancer in the Me-Can (metabolic syndromeand cancer) project [Text] / T. Bjørge, A. Lukanova, H. Jonsson [et al.] // CancerEpidemiol. Biomarkers Prev. – 2010. – Vol. 19, № 7. – P. 1737-1745.239.Moderate alcohol consumption during adult life, drinking patterns, andbreast cancer risk [Text] / W.Y.
Chen, B. Rosner, S.E. Hankinson [et al.] //JAMA. – 2011. – Vol. 306, № 17. – P. 1884-1890.240.Molecular Mechanisms Underlying Psychological Stress and Cancer [Text] /K.J. Shin, Y.J. Lee, Y.R. Yang [et al.] // Curr. Pharm. Des. – 2016. – Vol. 22,№ 16. – P. 2389-2402.241.Muggia, F. Bevacizumab in ovarian cancer: unanswered questions [Text] /F. Muggia // Drugs.
– 2012. – Vol. 72, № 7. – P. 931-936.242.Multiple high risk HPV infections are common in cervical neoplasia andyoung women in a cervical screening population [Text]/ K.S. Cuschieri,322H.A. Cubie, M.W. Whitley [et al.] // J. Clin. Pathol. – 2004. – Vol. 57, № 1. –P. 68-72.243.Multiple-type human papillomavirus (HPV) infections: a cross-sectionalanalysis of the prevalence of specific types in 309,000 women referred for HPVtesting at the time of cervical cytology [Text]/ E.L.
Dickson, R.I. Vogel, R.L. Bliss[et al.] // Int. J. Gynecol. Cancer. – 2013. – Vol. 23, № 7. – P. 1295-302.244.Natural history and prognosis of untreated stage I epithelial ovariancarcinoma [Text] / F.Y. Ahmed, E. Wiltshaw, R.P. A'Hern [et al.] // J. Clin.Oncol. – 1996. – Vol. 14, № 11. – P. 2968-2975.245.Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovariancancer [Text] / I. Vergote, C.G.
Tropé, F. Amant [et al.] // N. Engl.J. Med. – 2010. – Vol. 363, № 10. – P. 943-53.246.NHS Cervical Screening Programme : Annual Review, 2011 [Electronicresource] / ed. J. Patnick. – Sheffield, 2011. – Mode of access:http://www.cancerscreening.nhs.uk/cervical/publications/cervical-annualreview2011.pdf.247.No confirmed case of human papillomavirus DNA-negative cervicalintraepithelial neoplasia grade 3 or invasive primary cancer of the uterine cervixamong 511 patients [Text] / J. Bohmer, A.
van den Brule, O. Brummer [et al.] //Am. J. Obstet. Gynecol. – 2003. – Vol. 189, № 1. – P. 118-120.248.Obesity and Endometrial Cancer [Text] / E. Shaw, M. Farris, J. McNeil [etal.] // Recent Results Cancer Res. – 2016. – Vol. 208. – P. 107-136.249.OCEANS: a randomized, double-blind, placebo-controlled phase III trial ofchemotherapy with or without bevacizumab in patients with platinum-sensitiverecurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer [Text] /C. Aghajanian, S.V. Blank, B.A.
Goff [et al.] // J. Clin. Oncol. – 2012. – Vol. 30,№ 17. – P. 2039-2045.250.Optimal primary surgical treatment for advanced epithelial ovarian cancer[Text] / Elattar A. Bryant A., Winter-Roach B.A. [et al.] // Cochrane Database SystRev. – 2011. – Vol. 10, № 8. – Art. CD007565.323251.Ovarian_cancer_surgeryguidelines [Text]/ EuropeanSocietyofGynaecological Oncology. – Prague, Czech Republic, 2017. – 11 p.252.Parkin, D.M. Is the recent fall in incidence of post-menopausal breast cancerin UK related to changes in use of hormone replacement therapy? [Text] /D.M. Parkin // Eur. J. Cancer. – 2009.
– Vol. 45, № 9. – P. 1649-1653.253.Pathology and Genetics of Tumours of the Breast and Female Genital Organs[Text] / ed. by F.A. Tavassoli, P. Devilee ; World Health Organization,International Agency for Research on Cancer (IARC). – Lyon : IAPS Press,2003. – 432 p.254.Pelvic radiation with concurrent chemotherapy compared with pelvic andpara-aortic radiation for high-risk cervical cancer [Text] / M. Morris, P.J. Eifel,J. Lu [et al.] // N. Engl.
J. Med. – 1999. – Vol. 340, № 15. – P. 1137-1143.255.Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma [Text] / P.A. Vasey,G.C. Jayson, A. Gordon [et al.] // J. Natl. Cancer Inst. – 2004. – Vol. 96, № 22. –P. 1682-1691.256.Phase III trial comparing radical radiotherapy with and without cisplatinchemotherapy in patients with advanced squamous cell cancer of the cervix [Text] /R. Pearcey, M. Brundage, P. Drouin [et al.] // J. Clin. Oncol. – 2002. – Vol.
20,№ 4. – P. 966-972.257.Phase III trial of carboplatin and paclitaxel compared with cisplatin andpaclitaxel in patients with optimally resected stage III ovarian cancer: aGynecologic Oncology Group study [Text] / R.F. Ozols, B.N. Bundy, B.E. Greer[et al.] // J. Clin. Oncol. – 2003.
– Vol. 21, № 17. – P. 3194-3200.258.Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versusmoderately high-dose carboplatin followed by intravenous paclitaxel andintraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroupstudy of the Gynecologic Oncology Group, Southwestern Oncology Group, andEastern Cooperative Oncology Group [Text] / M. Markman, B.N. Bundy,D.S. Alberts [et al.] // J. Clin.
Oncol. – 2001. – Vol. 19, № 4. – P. 1001-1007.324259.Physician chemotherapy drug manual [Text] / [ed. by] E. Chu,V.T. DeVita. – Sudbury, Mass : Jones and Bartlett Publishers, 2013. – viii, 621 p.260.Pollak, M. Insulin and insulin-like growth factor signalling in neoplasia[Text] / M. Pollak // Nat Rev Cancer. – 2008. – Vol. 8, № 12. – P. 915-28.261.Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-termoutcome of the randomized PORTEC trial with central pathology review [Text] /A.N. Scholten, W.L. van Putten, H. Beerman [et al.] // Int. J.
Radiat. Oncol. Biol.Phys. – 2005. – Vol. 63, № 3. – P. 834-838.262.Prognostic value of HPV DNA status in cervical cancer before treatment: asystematic review and meta-analysis [Text] / P. Li, Y. Tan, L.X. Zhu [et al.] //Oncotarget. – 2017. – Vol. 8, № 39. – P. 66352-66359.263.Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18)L1 virus-like particle vaccine in young women: a randomised double-blindplacebo-controlled multicentre phase II efficacy trial [Text] / L.L. Villa,R.L. Costa, C.A. Petta [et al.] // Lancet Oncol.
– 2005. – Vol. 6, № 5. – P. 271-278.264.Ramachandran, B. Functional association of oestrogen receptors with HPVinfection in cervical carcinogenesis [Text] / B. Ramachandran // Endocr. Relat.Cancer. – 2017. – Vol. 24, № 4. – P. R99-R108.265.Randomized comparison of fluorouracil plus cisplatin versus hydroxyureaas an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix withnegative para-aortic lymph nodes: a Gynecologic Oncology Group and SouthwestOncology Group study [Text] / C.W.
Whitney, W. Sause, B.N. Bundy [et al.] //J. Clin. Oncol. – 1999. – Vol. 17, № 5. – P. 1339-1348.266.Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer [Text] / I.B. Vergote,L.N. Vergote-De Vos, V.M. Abeler [et al.] // Cancer. – 1992. – Vol. 69, № 3. –P. 741-749.267.Recent trends in type-specific HPV infection rates in the United States [Text]/ E.L. Dickson, R.I. Vogel, X.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
